Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

In Vivo Induction and in Vitro Inhibition of Hepatic Cytochrome P450 Activity by the Benzodiazepine Anticonvulsants Clonazepam and Diazepam

Raymond W. Nims, Russell A. Prough, Collins R. Jones, Diana L. Stockus, Konstantin H. Dragnev, Paul E. Thomas and Ronald A. Lubet
Drug Metabolism and Disposition June 1997, 25 (6) 750-756;
Raymond W. Nims
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell A. Prough
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Collins R. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana L. Stockus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantin H. Dragnev
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul E. Thomas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald A. Lubet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The ability of the benzodiazepines, as a chemical class, to cause the induction and/or inhibition of cytochromes P450 has not been well characterized. In the present study, the induction of the cytochrome P450 2B subfamily (CYP2B) in vivo and the inhibition of CYP2B activity in vitro by selected benzodiazepines was examined in hepatic tissues derived from male F344/NCr rats. Initial studies of the in vivo induction or in vitroinhibition of benzyloxyresorufin O-dealkylation activity revealed that both clonazepam and diazepam were relatively effective in vivo inducers of CYP2B when administered in the diet at 500 ppm for 5 days and also were fairly potent inhibitors of the activity of these hemoproteins in vitro. Oxazepam, in contrast, was ineffective as an inducer or an inhibitor of this activity. Further studies were performed to characterize the subfamily selectivity of the P450 induction and inhibition displayed by clonazepam. Specifically, microsomes from rats treated with clonazepam (1000 or 1800 ppm in the diet for 5 days) were found to be highly induced with respect to catalytic activities mediated by CYP2B, including benzyloxyresorufin and pentoxyresorufin O-dealkylation or testosterone 16β-hydroxylation, but other CYP proteins were minimally induced. In addition to inducing the CYP2B subfamily, clonazepam also induced the RNA encoding other drug metabolizing enzymes (e.g., epoxide hydrolase and the glutathione S-transferase α-subfamily) that are typically induced by phenobarbital-type inducers. Finally, clonazepam proved to be a potent noncompetitive or “mixed-type” competitive inhibitor of catalytic activities mediated by CYP2B, but not by other CYP proteins (e.g. CYP2A, CYP3A) in microsomes derived from phenobarbital-pretreated rats.

Footnotes

  • Send reprint requests to: Ronald A. Lubet, Ph.D., at: Chemoprevention Branch, National Cancer Institute, DCPC, EPN 201, 9000 Rockville Pike, Bethesda, MD 20892.

  • This work has been presented in part in abstract form (reference 46).

  • The work was supported in part by NIEHS Center grant ES05022 and RO1 grant GM 44982 (P.E.T.).

  • Abbreviations used are::
    BZR
    benzyloxyresorufin
    CLOT
    clotrimazole
    CZP
    clonazepam
    ETR
    ethoxyresorufin
    MTR
    methoxyresorufin
    PB
    phenobarbital
    PTR
    pentoxyresorufin
    S9
    post-mitochondrial supernatant
    • Received November 1, 1996.
    • Accepted February 10, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 25, Issue 6
1 Jun 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vivo Induction and in Vitro Inhibition of Hepatic Cytochrome P450 Activity by the Benzodiazepine Anticonvulsants Clonazepam and Diazepam
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

In Vivo Induction and in Vitro Inhibition of Hepatic Cytochrome P450 Activity by the Benzodiazepine Anticonvulsants Clonazepam and Diazepam

Raymond W. Nims, Russell A. Prough, Collins R. Jones, Diana L. Stockus, Konstantin H. Dragnev, Paul E. Thomas and Ronald A. Lubet
Drug Metabolism and Disposition June 1, 1997, 25 (6) 750-756;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

In Vivo Induction and in Vitro Inhibition of Hepatic Cytochrome P450 Activity by the Benzodiazepine Anticonvulsants Clonazepam and Diazepam

Raymond W. Nims, Russell A. Prough, Collins R. Jones, Diana L. Stockus, Konstantin H. Dragnev, Paul E. Thomas and Ronald A. Lubet
Drug Metabolism and Disposition June 1, 1997, 25 (6) 750-756;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Series-Compartment Models of Hepatic Elimination
  • Warfarin PBPK Model with TMDD Mechanism
  • Identification of payload-containing catabolites of ADCs
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics